VERU VERU INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 863894 · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.6%
TTM net income YoY59.4%
TTM EPS YoY—
Revenue 3-yr CAGR-34.9%
Net income 3-yr CAGR—
Margins
Gross margin34.7%
Operating margin-214.2%
Net margin-223.9%
FCF margin-129.3%
EBITDA margin-213.0%
Returns
ROE-145.4%
ROA-68.5%
ROIC (approx.)-327.4%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets46.5%
Debt / equity0.00x
Current ratio2.97x
Interest coverage-59.54x
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-29.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $16.89M | $16.30M | $39.35M | $61.26M |
| Cost of revenue | — | $11.03M | $8.73M | $8.76M | $13.33M |
| Gross profit | — | $5.85M | $7.57M | $30.59M | $47.93M |
| R&D expense | $15.59M | $12.78M | $51.20M | $70.91M | $32.69M |
| SG&A expense | $19.94M | $24.61M | $48.06M | $43.18M | $20.67M |
| Operating income | -$24.75M | -$36.17M | -$93.78M | -$83.49M | $12.97M |
| Interest expense | — | $607,470 | $2.43M | $4.37M | $4.89M |
| Pretax income | — | — | -$92.67M | -$83.80M | $4.27M |
| Income tax | $0 | $0 | $480,206 | $236,397 | -$3.13M |
| Net income | -$22.73M | -$37.80M | -$93.15M | -$84.04M | $7.39M |
| EBITDA | -$24.60M | -$35.90M | -$93.51M | -$83.35M | $13.07M |
| EPS (basic) | -1.55 | -2.80 | -1.10 | -1.05 | 0.10 |
| EPS (diluted) | — | — | -1.10 | -1.05 | 0.09 |
| Weighted avg. shares (diluted) | — | — | 84.97M | 80.12M | 83.80M |
| Balance sheet | |||||
| Cash & equivalents | $15.79M | $24.92M | $9.63M | — | — |
| Receivables | — | $3.96M | $4.51M | $3.55M | $8.79M |
| Inventory | — | $4.14M | $6.70M | $8.62M | $5.57M |
| Current assets | $18.92M | $35.22M | $22.93M | $104.00M | $151.75M |
| PP&E, net | $364,808 | $481,372 | $1.65M | $1.19M | $592,603 |
| Goodwill | $6.88M | $6.88M | $6.88M | $6.88M | $6.88M |
| Intangibles | — | $0 | $5,952 | $3.98M | $4.05M |
| Total assets | $29.84M | $60.42M | $50.02M | $135.36M | $178.15M |
| Current liabilities | $7.79M | $11.87M | $17.81M | $38.71M | $15.77M |
| Total liabilities | $11.50M | $28.10M | $30.34M | $52.56M | $25.85M |
| Shareholders' equity | $18.33M | $32.32M | $19.68M | $82.80M | $154.52M |
| Shares outstanding | 14.65M | 14.64M | 91.78M | 80.51M | 79.97M |
| Cash flow statement | |||||
| Operating cash flow | -$30.04M | -$21.68M | -$88.01M | -$47.51M | -$15.57M |
| Capital expenditure | $1,083 | $158,322 | $665,700 | $733,052 | $376,649 |
| Free cash flow | -$30.04M | -$21.84M | -$88.68M | -$48.24M | -$15.95M |
| Investing cash flow | $25.14M | $146,214 | $6.33M | $4.27M | $14.62M |
| Financing cash flow | -$4.22M | $36.83M | $11.11M | $1.07M | $109.72M |
| Depreciation & amortization | $152,105 | $268,177 | $269,874 | $138,000 | $98,000 |
| Stock-based compensation | $8.10M | $13.64M | $17.92M | $11.24M | $5.05M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.